What Has Been The Historical And Current Growth Of The Oncolytic Virus Therapy Market?
The oncolytic virus therapy market has seen considerable growth due to a variety of factors.
•Over the past few years, there has been a substantial escalation in the market size of oncolytic virus therapy. The estimated expansion is from $0.19 billion in 2024 to $0.23 billion in 2025, marking a compound annual growth rate (CAGR) of 25.4%.
This substantial growth during the historical period appears to be a result of advanced genetic engineering techniques, deeper insights into tumor microenvironments, successful clinical trials and regulatory approvals, increased utilization of immunotherapy for cancer treatment, and progress in gene delivery systems.
What Is The Forecast For The Oncolytic Virus Therapy Market By 2029?
The oncolytic virus therapy market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations for the oncolytic virus therapy market size point towards significant expansion in the coming years. It's predicted to surge to $0.55 billion by 2029, with a compound annual growth rate (CAGR) of 23.7%.
The predicted hike during the forecast period can be credited to factors like the growth of oncolytic virus platforms, combined therapies involving immune checkpoint inhibitors, personalized medicine strategies, the enlargement of the clinical trial environment, as well as regulatory backing and guidelines. The forecast period is also marked by several emerging trends including tech-savvy delivery systems, advancements in synthetic biology, joined efforts and partnerships within the biopharmaceutical industry, progress in virology and immunology, and increased focus on pediatric oncology.
Which Key Drivers Are Propelling The Oncolytic Virus Therapy Market's Growth?
The escalation in cancer instances is predicted to fuel the expansion of the oncolytic virus therapy market in the future. Cancer denotes a family of illnesses featuring the unrestrained proliferation and dispersion of anomalous cells within the body. Oncolytic virus therapy has the potential to specifically target and eliminate cancer cells, concurrently inducing an immune response against the tumor, thus delivering a dual action mode for effective cancer treatment. For example, the American Cancer Society Inc., a non-profit organization based in the US, forecasted in January 2023 that there would be 609,820 cancer fatalities and 1,958,310 new cancer diagnoses in the US in 2022. Consequently, the escalating frequency of cancer instances is fuelling the growth of the oncolytic virus therapy market.
What Are The Key Segments Within The Global Oncolytic Virus Therapy Market?
The oncolytic virus therapy market covered in this report is segmented –
1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types
2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses
3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer
4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes
Subsegments:
1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC), Other HSV-Based Therapies
2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015, AdV-5/3-D24, Other Adenovirus-Based Therapies
3) By Reovirus: Reolysin, Other Reovirus Therapies
4) By Poxviruses: JX-594 (OncoVac), Other Poxvirus Therapies
5) By NDV (Newcastle Disease Virus): NDV-Based Therapies, Other NDV Applications
6) By Other Therapy Types: Combination Therapies, Other Emerging Oncolytic Virus Therapies
Pre-Book The Oncolytic Virus Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Oncolytic Virus Therapy Market?
Key players in the oncolytic virus therapy market are focusing on securing regulatory consents to accelerate the launch of novel cancer therapies. Receiving regulatory approval implies gaining authorization from health departments after their assessment of various medical products such as drugs, biologics, and medical devices, before their introduction to the market. As an example, in March 2024, ImmVira, a biotech firm based in China, was granted Fast Track status by the FDA for its oncolytic virus therapy, MVR-T3011 IT for addressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), in patients whose disease has advanced after a course of platinum-based chemotherapy and a minimum of one previous line of anti-PD-1/PD-L1 therapy. The primary purpose of this Fast Track status is to quicken the developmental and evaluation phases for therapies targeted at severe diseases with unfulfilled medical requirements.
Who Are the Key Players in the Oncolytic Virus Therapy Market?
Major companies operating in the oncolytic virus therapy market include:
• Pfizer Inc.
• Johnson & Johnson
• Sorrento Therapeutics Inc.
• AbbVie Inc.
• AstraZeneca plc
• Amgen Inc.
• Boehringer Ingelheim Group
• Regeneron Pharmaceuticals
• Daiichi Sankyo Company Limited
• Kissei Pharmaceutical Co. Ltd.
• Takara Bio Inc.
• Oncorus Inc.
• Replimune Inc.
• Vyriad Inc.
• Genelux Corporation
• Oncolys BioPharma Inc.
• Adze Biotechnology
• Oncolytics Biotech Inc.
• TILT Biotherapeutics Ltd.
• Transgene SA
• Circio Holding ASA
• Lokon Pharma AB
• Provectus Biopharmaceuticals Inc.
• Vibalogics
What are the Regional Insights into the Oncolytic Virus Therapy Market?
North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
